ArticleScientific reports2026
Prognostic significance of POD24 in primary central nervous system diffuse large B-cell lymphoma: a retrospective study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A deep learning-based prognostic model for diffuse large B-cell lymphoma incorporating PET/CT imaging features.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) is a rare form of non-Hodgkin lymphoma with a notably poor prognosis. This study aimed to identify new prognostic factors for improved prognostic stratification in PCNS-DLBCL. A total of 85 PCNS-DLBCL cases from three hospitals were retrospectively analyzed. Disease progression within 24 months (POD24) and its risk factors were investigated, and a prognostic model for predicting POD24 was constructed. The median overall survival (mOS) and median progression-free survival (mPFS) for the entire cohort were 48.54 months and 39.09 months, respectively. Survival analysis indicated that age ≥ 65 years (HR = 4.05, P = 0.008), non-responsive disease (HR = 4.43, P = 0.004), and POD24 (HR = 25.22, P = 0.002) were independent poor prognostic factors for OS in PCNS-DLBCL. Further analysis revealed that independent risk factors for POD24 included elevated serum lactate dehydrogenase (LDH) levels (OR = 12.00, P = 0.03), elevated triglycerides (TG, OR = 4.88, P = 0.047), and non-responsive disease (OR = 9.39, P = 0.003). Subsequently, an "LDH-TG-Efficacy (LTE)" prognostic model for PCNS-DLBCL was constructed. The incidence of POD24 was significantly higher in the "LTE" high-risk group (≥ 1 point) compared to the low-risk group (0 points) (81.8% vs. 35%, P < 0.001). The receiver operating characteristic (ROC) curve determined that the area under the curve (AUC) for the "LTE" model was 0.828 (95% CI: 0.7282-0.927), with a sensitivity and specificity of 79.4% and 79.3%, respectively. Additionally, the prognosis of the "LTE" high-risk group was significantly worse. These findings demonstrated that POD24 might serve as an independent prognostic indicator for PCNS-DLBCL, and the "LTE" prognostic index may provide a reference for better identifying populations at risk for POD24.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.